{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:38:26Z","timestamp":1782448706829,"version":"3.54.5"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.breast.2023.02.006","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T02:56:55Z","timestamp":1676429815000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Regional radiotherapy after primary systemic treatment for cN+ breast cancer patients"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9173-279X","authenticated-orcid":false,"given":"Liesbeth J.","family":"Boersma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvil","family":"Mjaaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederieke","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.breast.2023.02.006_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejso.2018.09.027","article-title":"Vrancken peeters MTFD breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch breast cancer audit","volume":"45","author":"Spronk","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.breast.2023.02.006_bib2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0360-3016(02)02850-X","article-title":"Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy","volume":"53","author":"Buchholz","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.breast.2023.02.006_bib3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/bjs.5894","article-title":"Neoadjuvant chemotherapy for operable breast cancer","volume":"94","author":"Mieog","year":"2007","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.breast.2023.02.006_bib4","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1097\/SLA.0000000000004562","article-title":"Sentinel node biopsy alone or with axillary dissection in breast cancer patients after primary chemotherapy: long-term results of a prospective interventional study","volume":"276","author":"Martelli","year":"2022","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.breast.2023.02.006_bib5","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","article-title":"Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer","volume":"27","author":"Piltin","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.breast.2023.02.006_bib6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.breast.2023.02.006_bib7","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1245\/s10434-020-09211-0","article-title":"Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer","volume":"28","author":"Wong","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.breast.2023.02.006_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clbc.2021.06.003","article-title":"Regional nodal irradiation for clinically node-positive breast cancer patients with pathologic negative nodes after neoadjuvant chemotherapy","volume":"22","author":"Schlafstein","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.breast.2023.02.006_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/jpm11030172","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: preliminary experience with clinically node negative patients after systemic treatment","volume":"11","author":"Sanchez","year":"2021","journal-title":"J Personalized Med"},{"issue":"2","key":"10.1016\/j.breast.2023.02.006_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10549-020-06011-8","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach","volume":"186","author":"Damin","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.breast.2023.02.006_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0316","article-title":"Is regional nodal radiotherapy necessary for patients with cN1 and ypN0 breast cancer after neoadjuvant chemotherapy?-reply","volume":"8","author":"Barrio","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.02.006_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10549-022-06545-z","article-title":"Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol","volume":"193","author":"van Loevezijn","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2023.02.006_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer","volume":"114","author":"Offersen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2023.02.006_bib14","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial","author":"Bartels","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2023.02.006_bib15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","article-title":"Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial","volume":"8","author":"Krag","year":"2007","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.breast.2023.02.006_bib16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.breast.2023.02.006_bib17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa012782","article-title":"A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer","volume":"349","author":"Veronesi","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2023.02.006_bib18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(06)70947-0","article-title":"Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study","volume":"7","author":"Veronesi","year":"2006","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.02.006_bib19","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"49","key":"10.1016\/j.breast.2023.02.006_bib20","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1556\/OH.2013.29765","article-title":"Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial]","volume":"154","author":"S\u00e1volt","year":"2013","journal-title":"Orv Hetil"},{"issue":"6","key":"10.1016\/j.breast.2023.02.006_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.breast.2023.02.006_bib22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Morrow M effect of axillary dissection vs No axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.breast.2023.02.006_bib23","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. International Breast Cancer Study Group Trial 23-01","volume":"19","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.02.006_bib24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12885-017-3443-x","article-title":"Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)","volume":"17","author":"van Roozendaal","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.breast.2023.02.006_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0042-122853","article-title":"Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c\/iT1-2) in the context of breast conserving therapy: first results following commencement of the intergroup-sentinel-mamma (INSEMA) trial","volume":"77","author":"Reimer","year":"2017","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"9935","key":"10.1016\/j.breast.2023.02.006_bib26","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"McGale","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2023.02.006_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00044","article-title":"Offersen BV internal mammary node irradiation in patients with node-positive early breast cancer: fifteen-year results from the Danish breast cancer group internal mammary node study","author":"Thorsen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.02.006_bib28","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","volume":"21","author":"Poortmans","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.breast.2023.02.006_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1415340","article-title":"Regional nodal irradiation in early-stage breast cancer","volume":"373","author":"Whelan","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2023.02.006_bib30","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2023.02.006_bib31","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1245\/s10434-021-09897-w","article-title":"Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)","volume":"28","author":"Weiss","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.breast.2023.02.006_bib32","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","article-title":"How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study","volume":"23","author":"Mamtani","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.02.006_bib33","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1245\/s10434-019-07515-4","article-title":"Impact of residual nodal disease burden on technical outcomes of sentinel lymph node biopsy for node-positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy","volume":"26","author":"Laws","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.breast.2023.02.006_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study","volume":"27","author":"Classe","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.02.006_bib35","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijrobp.2003.10.037","article-title":"T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy","volume":"59","author":"Garg","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.breast.2023.02.006_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.2007.15.0326","article-title":"Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference","volume":"26","author":"Buchholz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2023.02.006_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/SLA.0b013e3182805c4a","article-title":"Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy","volume":"257","author":"Mittendorf","year":"2013","journal-title":"Ann Surg"},{"issue":"32","key":"10.1016\/j.breast.2023.02.006_bib38","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27","volume":"30","author":"Mamounas","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2023.02.006_bib39","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijrobp.2022.03.007","article-title":"Evaluating regional nodal irradiation allocation and association with oncologic outcomes in NSABP B-18, B-27, B-40, and B-41","volume":"113","author":"Vega","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.breast.2023.02.006_bib40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1186\/s12885-021-08423-1","article-title":"The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis","volume":"21","author":"Wang","year":"2021","journal-title":"J.BMC Cancer."},{"key":"10.1016\/j.breast.2023.02.006_bib41","first-page":"4105","article-title":"Locoregional recurrence-associated factors and risk-adapted postmastectomy radiotherapy for breast cancer staged in cT1-2N0-1 after neoadjuvant chemotherapy Cancer","volume":"10","author":"Wang","year":"2018","journal-title":"Manag Res"},{"issue":"3","key":"10.1016\/j.breast.2023.02.006_bib42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ijrobp.2015.11.005","article-title":"Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from ACOSOG Z1071 (alliance)","volume":"94","author":"Haffty","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.breast.2023.02.006_bib43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(22)00482-X","article-title":"De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study","volume":"23","author":"De Wild","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.02.006_bib44","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1245\/s10434-019-07635-x","article-title":"Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials","volume":"26","author":"Krug","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.breast.2023.02.006_bib45","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.prro.2016.08.009","article-title":"Postmastectomy radiotherapy: an American society of clinical oncology, American society for radiation oncology, and society of surgical oncology focused guideline update","volume":"6","author":"Recht","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.breast.2023.02.006_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.radonc.2021.06.032","article-title":"Postmastectomy radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy: a prelude to NSABP B-51?","volume":"162","author":"Haque","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2023.02.006_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jss.2020.12.007","article-title":"Impact of breast cancer pretreatment nodal burden and disease subtype on axillary surgical management","volume":"261","author":"Ng","year":"2021","journal-title":"J Surg Res"},{"issue":"6","key":"10.1016\/j.breast.2023.02.006_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0891","article-title":"EUBREAST group axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.breast.2023.02.006_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejrad.2014.09.020","article-title":"Lobbes MBI Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review","volume":"84","author":"Schipper","year":"2015","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1016\/j.breast.2023.02.006_bib50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semradonc.2022.01.003","article-title":"Regional nodal management after preoperative systemic therapy","volume":"32","author":"Singer","year":"2022","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"10.1016\/j.breast.2023.02.006_bib51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: TheSN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.breast.2023.02.006_bib52","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positivebreast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.breast.2023.02.006_bib53","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2023.02.006_bib54","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.breast.2023.02.006_bib55","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.02.006_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2022.3907","article-title":"Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer","author":"Simons","year":"2022","journal-title":"JAMA Surg"},{"issue":"10","key":"10.1016\/j.breast.2023.02.006_bib57","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.ejso.2021.06.024","article-title":"Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study","volume":"47","author":"Cab\u0131o\u011flu","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.breast.2023.02.006_bib58","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1245\/s10434-018-6404-y","article-title":"Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET\/CT and the MARI procedure","volume":"25","author":"Van der Noordaa","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.02.006_bib59","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clbc.2021.07.011","article-title":"MINIMAX Group.MINImal vs. MAXimal invasive xillary staging and treatment after neoadjuvant systemic therapy in node positive breast cancer: protocol of a Dutch multicenter registry study (MINIMAX)","volume":"22","author":"De Wild","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"10.1016\/j.breast.2023.02.006_bib60","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3390\/cancers13071565","article-title":"Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study","volume":"13","author":"Banys-Paluchowski","year":"2021","journal-title":"Cancers"},{"issue":"32","key":"10.1016\/j.breast.2023.02.006_bib61","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2014.56.5838","article-title":"Radiation field design in the ACOSOG Z0011 (alliance) trial","volume":"32","author":"Jagsi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.breast.2023.02.006_bib62","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2023.02.006_bib63","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1245\/s10434-020-08928-2","article-title":"Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy","volume":"28","author":"Almahariq","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2023.02.006_bib64","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","article-title":"Tailored axillary surgery in patients with clinically node-positive breast cancer: pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57-18, ABCSG-53, GBG 101)","volume":"60","author":"Weber","year":"2021","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.breast.2023.02.006_bib65","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(20)30580-5","article-title":"Poortmans PBreast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox","volume":"22","author":"Dubsky","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.breast.2023.02.006_bib66","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/bjs\/znac217","article-title":"Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey","volume":"109","author":"Gasparri","year":"2022","journal-title":"Br J Surg"},{"issue":"Suppl 3","key":"10.1016\/j.breast.2023.02.006_bib67","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1245\/s10434-015-4697-7","article-title":"The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation","volume":"22","author":"Yang","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.breast.2023.02.006_bib68","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1245\/s10434-015-4921-5","article-title":"Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy","volume":"23","author":"Swisher","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"10.1016\/j.breast.2023.02.006_bib69","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.19.02905","article-title":"Molecular predictive and prognostic markers in locoregional management","volume":"38","author":"Mamounas","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.02.006_bib70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jso.26252","article-title":"Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis","volume":"123","author":"Li","year":"2021","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.breast.2023.02.006_bib71","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10549-020-06015-4","article-title":"Zhang P Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy","volume":"185","author":"Liu","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2023.02.006_bib72","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00595-020-02157-6","article-title":"Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis","volume":"51","author":"Yokotani","year":"2021","journal-title":"Surg Today"},{"key":"10.1016\/j.breast.2023.02.006_bib73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semcancer.2020.04.002","article-title":"Radiomics in breast cancer classification and prediction","volume":"72","author":"Conti","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.breast.2023.02.006_bib74","first-page":"155","article-title":"Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications","volume":"19","author":"Croessmann","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"10.1016\/j.breast.2023.02.006_bib75","doi-asserted-by":"crossref","first-page":"397","DOI":"10.46883\/ONC.2020.3410.0397","article-title":"Strategies to optimize axillary surgery in patients with breast cancer receiving neoadjuvant endocrine therapy","volume":"34","author":"Weiss","year":"2020","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"10.1016\/j.breast.2023.02.006_bib76","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1245\/s10434-020-08905-9","article-title":"Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer: systematic literature review and NCDB analysis","volume":"27","author":"Stafford","year":"2020","journal-title":"Ann Surg Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:45:22Z","timestamp":1760777122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977623000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":76,"alternative-id":["S0960977623000292"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2023.02.006","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regional radiotherapy after primary systemic treatment for cN+ breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2023.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}